⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26323725 | 1.00 | — | — | |
| SCHEMBL26323727 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL10997501 | 0.97 | — | — | |
| SCHEMBL51157 | 0.81 | — | — | |
| SCHEMBL4011523 | 0.81 | — | — | |
| SCHEMBL7793314 | 0.78 | — | — | |
| SCHEMBL14262587 | 0.78 | — | — | |
| SCHEMBL7897509 | 0.77 | — | — | |
| SCHEMBL9921617 | 0.77 | — | — | |
| SCHEMBL13745480 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4503252-A | Process for the preparation of serinol and of serinol derivatives, and products obtained therefrom | EPROVA AKTIENGESELLSCHAFT (CH) | 1985-03-05 | — | — | US | claimed |
| EP-0025083-B1 | PROCESS FOR THE PREPARATION OF SERINOL AND SERINOL DERIVATIVES | EPROVA Aktiengesellschaft (CH) | 1982-02-03 | — | — | EP | claimed |
| US-12473295-B2 | Substituted straight chain spiro derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2025-11-18 | — | — | US | disclosed |
| WO-2024229253-A1 | METHODS AND TREATMENT OF VIRAL INFECTION CAUSED BY SARS-COV-2 WITH FUSED BICYCLIC HETEROCYCLIC COMPOUNDS AND USES THEREOF | Verge Analytics, Inc. (US) | 2024-11-07 | — | — | WO | disclosed |
| US-20230256001-A1 | MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230233468-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230142285-A1 | SUBSTITUTED STRAIGHT CHAIN SPIRO DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| WO-2022256299-A1 | 7-MORPHOLINO-5-(3-PHENYL-1 H-PYRAZOL-1 -YL)-FURO[3,2-B]PYRIDINE DERIVATIVES AND SIMILAR COMPOUNDS AS PIKFYVE KINASE INHIBITORS FOR THE TREATMENT OF E.G. AMYOTROPHIC LATERAL SCLEROSIS (ALS) | Verge Analytics, Inc. (US) | 2022-12-08 | — | — | WO | disclosed |
| US-10407409-B2 | 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20180186772-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | TAKEDA CALIFORNIA, INC. | 2018-07-05 | — | — | US | disclosed |
| EP-3336084-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE DERIVATIVES AND THEIR USE AS PHD INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2018-06-20 | — | — | EP | disclosed |
| US-7964613-B2 | (S)-3-amino-1-(4-bromo-5-isoquinolinesulfonyl)pyrrolidine; inhibits phosphorylation of myosin regulatory light chain; for spinal canal stenosis, spinal cord injury, rheumatoid arthritis, multiple sclerosis; Rho kinase inhibitors | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-06-21 | — | — | US | disclosed |
| US-20110008395-A1 | MIXED MICELLES INCLUDING AMPHIPATHIC CONJUGATES OF RNA AGENTS, AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR NIH | 2011-01-13 | — | — | US | disclosed |
| WO-2010067123-A1 | 2- (PIPERIDIN-1-YL) -4-HETEROCYCLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | WO | disclosed |
| US-20090048223-A1 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-19 | — | — | US | disclosed |
| US-20090048223-A1 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-1383498-A1 | CRF RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002087573-A1 | CRF RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2002-11-07 | — | — | WO | disclosed |
| US-4503252-A | Process for the preparation of serinol and of serinol derivatives, and products obtained therefrom | EPROVA AKTIENGESELLSCHAFT (CH) | 1985-03-05 | — | — | US | disclosed |
| US-4241053-A | ANTICARCONIGENIC AGENTS, ANTILEUKEMIC AGENT | TANABE SEIYAKU CO., LTD. (JP) | 1980-12-23 | — | — | US | disclosed |